Overview

Application of tPA in Suprachoroidal and Subretinal Hemorrhage

Status:
Recruiting

Trial end date:
2026-07-31

Target enrollment:
0

Participant gender:
All

Summary

Severe ocular rupture may be accompanied by suprachoroidal hemorrhage, or subretinal hemorrhage, or with suprachoroidal hemorrhage and subretinal hemorrhage. The suprachoroidal hemorrhage needs to be drained as soon as possible. In the process of waiting for the spontaneous liquefaction of hemorrhage, uncontrollable elevated intraocular pressure may occur, resulting in optic nerve injury, optic nerve atrophy, and visual loss. Tissue plasminogen activator can promote the liquefaction of blood clots. Studies have found that local application of tissue plasminogen activator in the suprachoroidal space can promote the liquefaction of the hemorrhage. Local application of tissue fibrinogen activator under the retina can promote the liquefaction of subretinal hemorrhage.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Plasminogen
Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

- Patients with severe ocular rupture accompanied by suprachoroidal hemorrhage, or
subretinal hemorrhage, or with suprachoroidal hemorrhage and subretinal hemorrhage

Exclusion Criteria:

- Rupture of eyeball accompanied by a small amount of suprachoroidal hemorrhage or a
small amount of subretinal hemorrhage